This study is in progress, not accepting new patients
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Summary
- Eligibility
- for people ages 60 years and up (full criteria)
- Location
- at Los Angeles 5368361, California 5332921 and other locations
- Dates
- study startedstudy ends around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Apellis Pharmaceuticals, Inc.
- ID
- NCT04770545
- Phase
- Phase 3 Macular Degeneration Research Study
- Study Type
- Interventional
- Participants
- Expecting 1200 study participants
- Last Updated